Drug intelligence / Profile preview

meningococcal C vaccine

Development stage: Unknown
Lead developer: Immunobiological Technology Institute (Bio-Manguinhos), Oswaldo Cruz Foundation (Fiocruz)
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Meningococcal C vaccine is a pharmaceutical drug classified as a vaccine. It provides active immunization against invasive meningococcal disease caused by *Neisseria meningitidis* serogroup C bacteria. The vaccine works by stimulating the body's immune system to produce specific antibodies that target and neutralize the serogroup C bacteria. This not only protects vaccinated individuals but also contributes to herd immunity by reducing the carriage of the bacteria in the throat within the population. It is typically administered via intramuscular injection.

Brand names: Menjugate CNeisVac CMeningitech
Other names: monovalent C meningococcal vaccine

Beyond the preview

Go deeper on meningococcal C vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on meningococcal C vaccine.

Explore the full profile